Last reviewed · How we verify
Morphine and Midazolam
Morphine and Midazolam is a Opioid analgesic and benzodiazepine sedative combination Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Acute pain management with sedation, Palliative care and end-of-life symptom management, Procedural sedation and analgesia.
Morphine is an opioid agonist that binds mu opioid receptors to reduce pain perception, while midazolam is a benzodiazepine that enhances GABA inhibitory signaling to produce sedation and anxiolysis.
Morphine is an opioid agonist that binds mu receptors to provide analgesia and sedation, while midazolam is a benzodiazepine that enhances GABA inhibitory neurotransmission to produce anxiolysis and sedation. Used for Acute pain management with sedation, Palliative care and end-of-life symptom management, Procedural sedation and analgesia.
At a glance
| Generic name | Morphine and Midazolam |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Opioid analgesic and benzodiazepine sedative combination |
| Target | Mu opioid receptor; GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management, Palliative care, Acute care sedation |
| Phase | FDA-approved |
Mechanism of action
Morphine acts as a mu opioid receptor agonist in the central and peripheral nervous systems, modulating pain transmission and perception. Midazolam potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission to produce sedative, anxiolytic, and muscle relaxant effects. Together, this combination provides analgesia and sedation, commonly used in acute care and palliative settings.
Approved indications
- Acute pain management with sedation
- Palliative care and end-of-life symptom management
- Procedural sedation and analgesia
Common side effects
- Respiratory depression
- Hypotension
- Sedation/drowsiness
- Nausea
- Constipation
- Dizziness
Key clinical trials
- Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture (PHASE3)
- Morphine, Midazolam and Dexmedetomidine in the Management of Acute Cardiogenic Pulmonary Edema, Safety and Efficacy (PHASE1)
- General Versus Regional Anesthesia in Peripheral Arterial Surgery (NA)
- The Effect of Superficial Parasternal Intercostal Plane Block on Pulmonary Function Tests After Cardiac Surgery (NA)
- Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair (PHASE4)
- Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine and Midazolam CI brief — competitive landscape report
- Morphine and Midazolam updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Morphine and Midazolam
What is Morphine and Midazolam?
How does Morphine and Midazolam work?
What is Morphine and Midazolam used for?
Who makes Morphine and Midazolam?
What drug class is Morphine and Midazolam in?
What development phase is Morphine and Midazolam in?
What are the side effects of Morphine and Midazolam?
What does Morphine and Midazolam target?
Related
- Drug class: All Opioid analgesic and benzodiazepine sedative combination drugs
- Target: All drugs targeting Mu opioid receptor; GABA-A receptor
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Pain management, Palliative care, Acute care sedation
- Indication: Drugs for Acute pain management with sedation
- Indication: Drugs for Palliative care and end-of-life symptom management
- Indication: Drugs for Procedural sedation and analgesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing